Same Mutation, Different Fate
When MRD testing evolves from a numerical readout into a definition of clonal behavior, it becomes what clinicians have needed all along: a tool that informs action, not just detection.
FDA approves first NGS test to detect minimal residual disease in two blood cancers
In a first, the agency approved Adaptive Biotechnologies' clonoSEQ assay to detect MRD in acute lymphoblastic leukemia and multiple myeloma, a measure that can predict risk of relapse.
NEMT Partner Guide: Why Payers and Providers Should Choose MediDrive’s TMS
Alan Murray on improving access for medical transportation.